Preformed donor‐reactive T cells are relatively resistant to standard immunosuppression and account for an increased incidence of T cell‐mediated rejection (TCMR) and inferior kidney allograft outcomes. We analyzed 150 living… Click to show full abstract
Preformed donor‐reactive T cells are relatively resistant to standard immunosuppression and account for an increased incidence of T cell‐mediated rejection (TCMR) and inferior kidney allograft outcomes. We analyzed 150 living donor kidney transplant recipients (KTRs) of a first kidney allograft. Ninety‐eight ABO‐compatible (ABOc) and 52 ABO‐incompatible (ABOi) KTRs were included. Samples were collected at 6 time points, before rituximab, before immunoadsorption and pretransplantation, at +1, +2, and +3 months posttransplantation, and donor‐reactive T cells were measured by interferon‐γ ELISPOT assay. Twenty of 98 ABOc (20%) and 12 of 52 ABOi KTRs (23%) showed positive pretransplant ELISPOT. Eight of 20 ABOc‐KTRs (40%) with positive pretransplant ELISPOT showed TCMR, whereas 17 of 78 ABOc‐KTRs (22%) with negative pretransplant ELISPOT did (P = 0.148). Seven of 12 ABOi KTRs (57%) with positive pretransplant ELISPOT showed TCMR, whereas only 3 of 40 ABOi KTRs (8%) with negative pretransplant ELISPOT did (P < 0.001). Interestingly, 6 of 7 ABOi KTRs with positive pretransplant ELISPOT that persists after ABO desensitization developed TCMR. Among 118 KTRs with negative pretransplant ELISPOT, 10 of 72 ABOc‐KTRs (14%), but 0 of 46 ABOi KTRs, developed positive posttransplant ELISPOT (P = 0.006). Preformed donor‐reactive T cells that persist despite ABO desensitization identify KTRs at highest risk of TCMR. Less de‐novo donor‐reactive T cells after ABO desensitization may account for less TCMR. Both, the use of rituximab and early initiation of calcineurin inhibitor‐based maintenance immunosuppression may contribute to these findings.
               
Click one of the above tabs to view related content.